UMLS. CSP-HL7-ICD9CM-NCI-NDFRT-RXNORM
%
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
selected terms: 70,266 page 4 of 703

301. *Mass
[The amount of matter in an object. ( NCI )] (UMLS (HL7) C1306372) Mass =Quantitative Concept =Kind of quantity;
351. *Volume Ratio
(UMLS (HL7) C1547056) =Quantitative Concept =Kind of quantity;
302. *Mass Concentration
[A concentration unit measured as the mass of solute per volume of mixture. ( NCI )] (UMLS (HL7) C0560150) =Quantitative Concept =Kind of quantity;
352. .alpha.-Linolenic acid
[An essential fatty acid belonging to the omega-3 fatty acids group. It is highly concentrated in certain plant oils and has been reported to inhibit the synthesis of prostaglandin resulting in reduced inflammation and prevention of certain chronic diseases. ( NCI )] (UMLS (NCI) C0051405) =Lipid; Biologically Active Substance ;
=Fatty Acids, Omega-3;
Linolenic Acids =LINOLENIC ACID
303. *Mass Concentration Ratio
(UMLS (HL7) C1264678) =Quantitative Concept =Kind of quantity;
353. .beta.,.beta.'-Dichlorodiethylaniline
[An alkylating mustard with antineoplastic activity. Aniline mustard forms covalent linkages with nucleophilic centers, resulting in depurination, base miscoding and strand scission, and crosslinking of DNA strands, all of which contribute to its cytotoxicity. (NCI04) ( NCI )] (UMLS (NCI) C0003040) =Organic Chemical; Pharmacologic Substance
304. *Mass Fraction
[Quotient of the mass of a component and the total mass of the system containing the component. For clinical chemistry the term component is recommended, IS0 uses substance. For clinical chemistry the term system is recommended, IS0 uses mixture. ( NCI )] (UMLS (HL7) C1264663) Mass Fraction;
=Quantitative Concept =Kind of quantity;
354. .beta.,.beta.-Dimethylcysteine
[beta dimethyl analog of cysteine; USP lists as a chelating agent. ( CSP )] (UMLS (NCI) C0030817) =Amino Acid, Peptide, or Protein; Pharmacologic Substance =Amino Acids, Sulfur;
[MS100] ANTIRHEUMATICS;
chelating agent;
.beta.,.beta.-Dimethylcysteine =PENICILLAMINE 125 MG;
PENICILLAMINE 250 MG;
.beta.,.beta.-Dimethylcysteine;
305. *Mass Increment
(UMLS (HL7) C1264694) =Quantitative Concept =Kind of quantity;
355. .beta.-2'-Deoxy-6-thioguanosine
[A thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication. This agent is cytotoxic against leukemia cell lines and has demonstrated some activity against leukemia cells in vivo. Beta-thioguanine deoxyriboside demonstrates antineoplastic activity against 6-thioguanine-resistant tumor cells. (NCI04) ( NCI )] (UMLS (NCI) C0053376) =Organic Chemical; Pharmacologic Substance; Biologically Active Substance
306. *Mass Rate
(UMLS (HL7) C1264669) =Quantitative Concept =Kind of quantity;
356. .beta.-Carotene
[A vitamin A precursor. Beta carotene belongs to the family of fat-soluble vitamins called carotenoids. ( NCI )] (UMLS (NCI) C0053396) =Organic Chemical; Pharmacologic Substance; Vitamin =carotene;
[VT050] VITAMIN A;
TO BE DELETED INGREDIENT PREPARATIONS;
=VITAMIN A (AS ACETATE & BETA CAROTENE);
VITAMIN A (AS PALMITATE & BETA CAROTENE);
BETA CAROTENE 0.25 MG/240ML;
BETA CAROTENE 1.06 MG/L;
BETA CAROTENE 400 UNT;
BETA CAROTENE 6000 UNT;
Beta Carotene 25000 UNT;
Beta Carotene 1000 UNT;
Beta Carotene 50 MG;
Beta Carotene 10000 UNT;
Beta Carotene 30 MG;
Beta Carotene 25 MG
307. *Mass Ratio
(UMLS (HL7) C1264679) =Quantitative Concept =Kind of quantity;
357. .beta.-Cytosine arabinoside
[class of pyrimidine nucleoside analogs used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia; antimetabolite antineoplastic agents that inhibit the synthesis of DNA with actions specific for the S phase of the cell cycle; also have antiviral and immunosuppressant properties. ( CSP )] (UMLS (NCI) C0010711) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
=[AN300] ANTINEOPLASTICS, ANTIMETABOLITES;
arabinonucleoside;
cytidine;
cytosine nucleoside =1,3, 5-Triazin-2(1H)-one, 4-amino-1-.beta.-D- arabinofuranosyl- (9CI);
Cytarabine Liposome;
CYTARABINE 2 GM/VIL;
CYTARABINE 1 GM/VIL;
CYTARABINE 100 MG;
CYTARABINE 500 MG;
308. *Number
[A numeral or string of numerals expressing value, quantity, or identification. ( NCI )] (UMLS (HL7) C0237753) =Quantitative Concept ;
=Kind of quantity;
358. .beta.-Pyrazomycin
[A nucleoside analog. Pyrazofurin potently inhibits orotidine 5'-monophosphate (OMP) decarboxylase, thereby interfering with de novo synthesis of uridine nucleotides and resulting in cytotoxicity. This agent also causes a rapid depletion of the pyrimidine deoxynucleotide pool, thereby inhibiting DNA synthesis and cell replication. (NCI04) ( NCI )] (UMLS (NCI) C0072661) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance
309. *Number Concentration
(UMLS (HL7) C1264651) =Quantitative Concept =Kind of quantity;
359. .delta.-Aminolevulinic acid hydrochloride
[The hydrochloride salt form of aminolevulinic acid, an aminoketone, used for local photosensitizing therapy. Aminolevulinic acid (ALA) is a metabolic pro-drug that is converted into the photosensitizer protoporphyrin IX (PpIX), which accumulates intracellularly. Upon exposure to light of appropriate wavelength (red, or blue), PpIX catalyzes oxygen to singlet oxygen, an intracellular toxin, which can further react to form superoxide and hydroxyl radicals. This leads to cellular cytotoxic effects. ( NCI )] (UMLS (NCI) C0876231) 5-Amino-4-oxopentanoic Acid HCl;
5-Amino-4-oxopentanoic Acid Hydrochloride;
Aminolevulinic Acid HCl;
AMINOLEVULINIC ACID HYDROCHLORIDE;
Delta-Aminolevulinic Acid HCl;
Delta-Aminolevulinic Acid Hydrochloride =Organic Chemical; Pharmacologic Substance ;
310. *Number Content
(UMLS (HL7) C1264658) =Quantitative Concept =Kind of quantity;
360. .delta.1-Cortisone
[synthetic anti-inflammatory glucocorticoid derived from cortisone; biologically inert and converted to prednisolone in the liver. ( CSP )] (UMLS (NCI) C0032952) =Steroid; Pharmacologic Substance; Hormone =[HS051] GLUCOCORTICOIDS;
Pregnadienediols;
corticosteroid analog;
=PREDNISONE MISC. POWDER (GM);
PREDNISONE 1 MG/ML;
PREDNISONE 2.5 MG;
PREDNISONE 20 MG;
PREDNISONE 25 MG;
PREDNISONE 5 MG/ML;
PREDNISONE 50 MG;
PREDNISONE 1 MG;
PREDNISONE 10 MG;
prednisolone 1 MG/ML;
PREDNISONE 5 MG
311. *Number Fraction
(UMLS (HL7) C1264664) =Quantitative Concept =Kind of quantity;
361. .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyric acid
[nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others; may be a carcinogen. ( CSP )] (UMLS (NCI) C0008163) =Organic Chemical; Pharmacologic Substance; Hazardous or Poisonous Substance =[AN000] ANTINEOPLASTICS;
Nitrogen Mustard Compound;
Antineoplastic Alkylating Agent;
haloalkylamine =CHLORAMBUCIL 2 MG;
312. *Number Ratio
(UMLS (HL7) C1264680) =Quantitative Concept =Kind of quantity;
362. .omega.-Diethylamino-2,6-dimethylacetanilide
[drug having anesthetic, sedative, analgesic, anticonvulsant and cardiac depressant activities, used as a local anesthetic; applied topically to the skin and mucous membranes. ( CSP )] (UMLS (NCI) C0023660) =Organic Chemical; Pharmacologic Substance =Acetanilides;
local anesthetic;
phenylamide;
[DE700] LOCAL ANESTHETICS, TOPICAL;
[NT300] ANESTHETICS, MUCOSAL;
=2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide Monohydrochloride;
LIDOCAINE MISC. POWDER (GM);
Lidocaine 0.04 MG/MG;
LIDOCAINE 3 %;
LIDOCAINE 5 MG;
LIDOCAINE 1 %;
LIDOCAINE 4 %;
LIDOCAINE 5 %;
LIDOCAINE 10 %;
LIDOCAINE 0.4 %;
LIDOCAINE 2.5 %
313. *Osmolality
(UMLS (HL7) C1547034) =Quantitative Concept =Kind of quantity;
363. /uL
[A volume unit equal to one microliter used as a denominator to build a derived unit expressed as a ratio. ( NCI )] (UMLS (NCI) C1300557) Per Cubic Millimeter;
Per mcl;
Per Microliter;
Per uL =Quantitative Concept
314. *Pressure (Partial)
(UMLS (HL7) C0030604) =Natural Phenomenon or Process ;
=Kind of quantity;
364. 0-11 years old
[header term for indexing children when age groups are unknown; if age groups are given index most specific age. ( CSP )] (UMLS (CSP) C0008059) =Age Group =Age categories;
RoleClass =12-20 years old;
child (0-11);
Toddler;
Young child;
Older child;
315. *Ranges
[The difference between the lowest and highest numerical values. ( NCI )] (UMLS (HL7) C1514721) Range;
=Quantitative Concept ;
=Kind of quantity;
365. 0-6 weeks old
[an infant human from birth through 6 weeks of age; also index with appropriate human and clinical research terms. ( CSP )] (UMLS (CSP) C0021289) =Age Group =baby;
infant human (0-1 year) =low birth weight infant human;
Premature Infant
316. *Ratios
(UMLS (HL7) C1610540) =Quantitative Concept =Kind of quantity;
366. 06-Benzyl Guanine
[A drug that may improve the response of cancer cells to chemotherapy. ( NCI )] (UMLS (NCI) C0083812) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance
317. *Reciprocal Relative Time
(UMLS (HL7) C1547038) =Quantitative Concept =Kind of quantity;
367. 1
[Maxillary right third molar ( HL7V3.0 )] (UMLS (HL7) C0227032) tooth 1 =Body Part, Organ, or Organ Component =Permanent dentition;
318. *Relative
(UMLS (HL7) C1547039) =Quantitative Concept =Kind of quantity;
368. 1
[The first step in testing a new treatment in humans. These studies test the best way to give a new treatment (for example, by mouth, intravenous infusion, or injection) and the best dose. The dose is usually increased a little at a time in order to find the highest dose that does not cause harmful side effects. Because little is known about the possible risks and benefits of the treatments being tested, phase I trials usually include only a small number of patients who have not been helped by other treatments. ( NCI )] (UMLS (NCI) C0920321) clinical trial phase I;
Clinical Trials, Phase I;
Early-Stage Clinical Trials;
Phase 1 Study;
Phase I Clinical Trials;
Phase I Protocol;
Phase I Study;
phase I trial;
Trial Phase 1 =Research Activity =clinical trial;
319. *Relative Density
(UMLS (HL7) C1576416) =Qualitative Concept =Kind of quantity;
369. 1 aminocyclopentyl 1,3 dicarboxylate
[ ] (UMLS (CSP) C0044270) =Organic Chemical; Pharmacologic Substance ;
320. *Relative Mass Concentration
(UMLS (HL7) C1264645) =Quantitative Concept =Kind of quantity;
370. 1 benzazine
[bicyclic aromatic ring structure with one ortho nitrogen. ( CSP )] (UMLS (CSP) C0034424) =Organic Chemical =2-Ring Heterocyclic Compound;
nitrogenous heterocyclic compound =chloroquine;
PRIMAQUINE;
quinolinate;
kynurenate;
cyanine;
Aminoquinolines;
Hydroxyquinolines;
MEFLOQUINE;
Nitroquinolines;
QUINIDINE;
(-)-Quinine;
Quinolones;
flosequinan;
SAQUINAVIR;
MONTELUKAST
321. *Relative Substance Concentration
(UMLS (HL7) C1264647) =Quantitative Concept =Kind of quantity;
371. 1 carbon compound
[ ] (UMLS (CSP) C0597700) =Organic Chemical ;
=Organic Chemical;
322. *Relative Time
(UMLS (HL7) C1547040) =Quantitative Concept =Kind of quantity;
372. 1 carbon transferase
[ ] (UMLS (CSP) C0597701) =Amino Acid, Peptide, or Protein; Enzyme =EC 2;
=EC 2.1.1;
formininotransferase;
carboxyltransferase/carbamoyltransferase
323. *Saturation Fraction
(UMLS (HL7) C1547041) =Quantitative Concept =Kind of quantity;
373. 1 DEG BURN BACK OF HAND
[ ] (UMLS (ICD9CM) C0161218) =Injury or Poisoning
324. *Substance Amount
(UMLS (HL7) C1264637) =Quantitative Concept =Kind of quantity;
374. 1 DEG BURN FINGR W THUMB
[ ] (UMLS (ICD9CM) C1112529) Erythema due to burn [first degree] of two or more digits of hand including thumb =Injury or Poisoning
325. *Substance Concentration
(UMLS (HL7) C0457929) =Quantitative Concept =Kind of quantity;
375. 1 EXTRAOC MUSCL ADVANCE
[ ] (UMLS (ICD9CM) C0176283) =Therapeutic or Preventive Procedure
326. *Substance Concentration Increment
(UMLS (HL7) C1264654) =Quantitative Concept =Kind of quantity;
376. 1 EXTRAOC MUSCL RESECT
[ ] (UMLS (ICD9CM) C0197958) =Therapeutic or Preventive Procedure
327. *Substance Concentration Ratio
(UMLS (HL7) C1264681) =Quantitative Concept =Kind of quantity;
377. 1 EYE-SEV/OTH-BLIND NOS
[ ] (UMLS (ICD9CM) C0392562) =Disease or Syndrome ;
328. *Substance Content
(UMLS (HL7) C1547042) =Quantitative Concept =Kind of quantity;
378. 1 hour post challenge
(UMLS (HL7) C1547065) =Temporal Concept =Time delay post challenge;
329. *Substance Content Rate
(UMLS (HL7) C1264670) =Quantitative Concept =Kind of quantity;
379. 1 INT MAM-COR ART BYPASS
[Direct myocardial revascularization in which the internal mammary artery is anastomosed to the right coronary artery, circumflex artery, or anterior descending coronary artery. The internal mammary artery is the most frequent choice, especially for a single graft, for coronary artery bypass surgery. ( MSH )] (UMLS (ICD9CM) C0021781) =Therapeutic or Preventive Procedure ;
330. *Substance Fraction
(UMLS (HL7) C1264665) =Quantitative Concept =Kind of quantity;
380. 1 minute post challenge
(UMLS (HL7) C1547067) =Temporal Concept =Time delay post challenge;
331. *Substance Rate
(UMLS (HL7) C1264671) =Quantitative Concept =Kind of quantity;
381. 1 month (30 days) post challenge
(UMLS (HL7) C1547066) =Temporal Concept =Time delay post challenge;
332. *Substance Ratio
(UMLS (HL7) C1264682) =Quantitative Concept =Kind of quantity;
382. 1 or More Positive Axillary Nodes
[Presence of one or more lymph nodes in the area of the armpit in which cancerous cells have been detected. ( NCI )] (UMLS (NCI) C0279784) =Finding
333. *Susceptibility
(UMLS (HL7) C1547045) =Quantitative Concept =Kind of quantity;
383. 1 year old
[ ] (UMLS (CSP) C0920381) =Age Group ;
334. *Temperature
[a specific degree of hot or cold as indicated on or referred to a standard scale. ( CSP )] (UMLS (HL7) C0039476) =Quantitative Concept ;
=Physical Phenomenon;
Kind of quantity =Cold;
heat
384. 1'-Demethyl-1'-nitroso-nicotine
[A yellow, oily liquid nitrosamine that solidifies at cold temperatures and emits toxic fumes of nitrogen oxides when heated to decomposition. Nitrosonornicotine is found in tobacco products and is likely produced by the nitrosation of nicotine during the making and smoking of tobacco products. This substance is only used in research to induce tumors in experimental animals. Exposure to nitrosonornicotine affects the liver and nitrosonornicotine is reasonably anticipated to be a human carcinogen. (NCI05) ( NCI )] (UMLS (NCI) C0067113) =Organic Chemical; Hazardous or Poisonous Substance ;
335. *Temperature Difference
(UMLS (HL7) C1547047) =Quantitative Concept =Kind of quantity;
385. 1(2H)-Phthalazinone Hydrazone
[direct-acting vasodilator that is used as an antihypertensive. ( CSP )] (UMLS (NCI) C0020223) =Organic Chemical; Pharmacologic Substance =antihypertensive agent;
hydrazine;
Phthalazines;
[CV490] ANTIHYPERTENSIVES, OTHER =HYDRALAZINE HYDROCHLORIDE;
HYDRALAZINE 50 MG
336. *Temperature Increment
(UMLS (HL7) C1547048) =Quantitative Concept =Kind of quantity;
386. 1(2H)-Phthalazinone, 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, Monohydrochloride
[The hydrochloride salt form of azelastine, a phthalazinone derivative with antihistaminergic activity. Azelastine hydrochloride competes with histamine for the H1 receptor, thereby diminishing the actions of histamine on effector cells and decreasing the histamine-mediated symptoms of allergic reaction, such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of gastrointestinal smooth muscle. ( NCI )] (UMLS (NCI) C0771004) Azelastine Hydrochloride;
AZELASTINE HYDROCHLORIDE PREPARATION;
W-2979M =Organic Chemical; Pharmacologic Substance =AZELASTINE;
=AZELASTINE HYDROCHLORIDE 0.05 %;
AZELASTINE HYDROCHLORIDE 137 MCG/ACTUAT
337. *Threshold Mass Concentration
(UMLS (HL7) C1264644) =Quantitative Concept =Kind of quantity;
387. 1(2H)-Pyrimidinecarboxamide, 5-fluoro-N-hexyl-3,4-dihydro-2,4-dioxo-
[An antimetabolite (pyrimidine analogue) antineoplastic derivative of 5-fluorouracil. (NCI) ( NCI )] (UMLS (NCI) C0044401) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
338. *Threshold Substance Concentration
(UMLS (HL7) C1264646) =Quantitative Concept =Kind of quantity;
388. 1(3-hydroxy-2-phosphonomethoxypropyl) Cytosine
[1(3-hydroxy-2-phosphonomethoxypropyl) cytosine; potent selective inhibitor of human cytomegalovirus replication; used in CMV retinitis therapy. ( CSP )] (UMLS (NCI) C0286079) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
=[AM800] ANTIVIRALS;
4-Amino-2(1H)-pyrimidinone;
Organophosphorus Compounds;
cytosine analog =CIDOFOVIR 75 MG/ML
339. *Time (e.g. seconds)
[The continuum of experience in which events pass from the future through the present to the past; a specific point in this continuum or the interval separating two points. ( NCI )] (UMLS (HL7) C0040223) =Temporal Concept ;
=Kind of quantity;
389. 1(3H)Isobenzofuranone,6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3,-dioxolo(4,5-g)isoquinolin-5-yl)-hydrochloride
[The orally available hydrochloride salt of the opioid agonist noscapine, a phthalideisoquinoline alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine binds to tubulin and alters its conformation, resulting in a disruption of the dynamics of microtubule assembly (by increasing the time that microtubules spend idle in a paused state) and, subsequently, the inhibition of mitosis and tumor cell death. Unlike other tubulin inhibitors such as the taxanes and vinca alkaloids, noscapine does not affect microtubule polymerization. ( NCI )] (UMLS (NCI) C1450474) Narcotine hydrochloride;
Noscapine HCl;
Noscapine Hydrochloride;
=Organic Chemical; Pharmacologic Substance ;
340. *Time Difference
(UMLS (HL7) C1547049) =Quantitative Concept =Kind of quantity;
390. 1, 4-Benzenedicarboximidamide, N, N''-bis[4-[imino(methylamino)methyl]phenyl]-, tetrahydrochloride
[One of 800 terephthalanilides synthesized and tested preclinically in the late 1950's and early 1960's. Chosen in the 1990's for further clinical investigation by the NCI's Project for the Review of Old Drugs because of its structure and activity spectrum. ( NCI )] (UMLS (NCI) C1510442) Amidino TIC;
Terephthalamidine, N, N''-bis[p-(methylamidino)phenyl]-, tetrahydrochloride =Organic Chemical; Pharmacologic Substance ;
341. *Time Ratio
(UMLS (HL7) C1547051) =Temporal Concept =Kind of quantity;
391. 1, 4-Bis[methanesulfonoxy]butane
[alkylating agent having a selective immunosuppressive effect on bone marrow; has been used in the palliative treatment of chronic myeloid leukemia. ( CSP )] (UMLS (NCI) C0006463) =Organic Chemical; Pharmacologic Substance; Hazardous or Poisonous Substance =Alkylating Activity;
[AN000] ANTINEOPLASTICS;
Butylene Glycols;
Mesylates;
mesylate;
Antineoplastic Alkylating Agent =BUSULFAN 6 MG/ML;
BUSULFAN 2 MG
342. *Time Stamp — Date and Time
(UMLS (HL7) C1547050) =Quantitative Concept =Kind of quantity;
392. 1, 5-dihydro-5-methyl-1-(5-O-phosphono-.beta.-D-ribofuranosyl)-1,4,5, 6,8-pentaazaacenaphthylen-3-amine
[A tricyclic nucleoside with potential antineoplastic activity. As a purine analog, triciribine phosphate inhibits the enzymes amidophosphoribosyltransferase and inosine monophosphate dehydrogenase, resulting in decreased purine nucleotide biosynthesis, decreased DNA and protein synthesis, and cell cycle arrest. This agent may also exhibit antiviral activity. (NCI04) ( NCI )] (UMLS (NCI) C0077070) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance
343. *Type
(UMLS (HL7) C1547052) =Quantitative Concept =Kind of quantity;
393. 1,1',1"-phosphinothioylidynetrisaziridine
[alkylating agent used as an antineoplastic in the treatment of carcinoma of the breast, ovary, and bladder, malignant infusions and lymphomas. ( CSP )] (UMLS (NCI) C0039871) =Organophosphorus Compound; Pharmacologic Substance; Hazardous or Poisonous Substance =[AN000] ANTINEOPLASTICS;
Organothiophosphorus Compounds;
Triethylenephosphoramide;
Aminoethylene;
Antineoplastic Alkylating Agent;
=THIOTEPA 15 MG
344. *Velocity
(UMLS (HL7) C1547053) =Quantitative Concept =Kind of quantity;
394. 1,1'-(2,2,2-Trichloroethylidene)-bis[4-chlorobenzene]
[insecticide that came into prominence during and after World War II; for a time it proved very effective, but insect populations rapidly developed tolerance for it, hence much of its original effectiveness has been lost; general usage is now widely discouraged because of the toxicity that results from the environmental persistence of this agent. ( CSP )] (UMLS (NCI) C0011041) =Organic Chemical; Hazardous or Poisonous Substance =chlorohydrocarbon insecticide;
345. *Velocity Ratio
(UMLS (HL7) C1547054) =Quantitative Concept =Kind of quantity;
395. 1,1'-(2,3-Dimethyl-1,4-butanediyl)bis(3,4-dimethoxybenzene)
[A semi-synthetic nordihydroguaiaretic acid (NDGA) derivative and transcriptional inhibitor with potential antiviral and antitumor activity. Tetra-O-methyl nordihydroguaiaretic acid competes with the transcription factor Sp1 for specific Sp1 DNA binding domains within gene promoter regions during DNA synthesis. In viral-infected cells, blocking of the Sp1 binding site suppresses Sp1-regulated viral promoter activity and gene expression, thereby inhibiting viral transcription and replication. In tumor cells, blockage of Sp1 binding sites by this agent interferes with the transcription of the Sp1-dependant genes cyclin-dependant kinase (Cdc2) and survivin, both overexpressed in many cancers. By suppressing Sp1-regulated transcription, tetra-O-methyl nordihydroguaiaretic acid inhibits the production of cdc2 and survivin leading to a reduction of tumor cell proliferation and an induction of apoptosis. ( NCI )] (UMLS (NCI) C0654036) =Organic Chemical; Pharmacologic Substance ;
346. *Viscosity
(UMLS (HL7) C1547055) =Quantitative Concept =Kind of quantity;
396. 1,1'-Bi(ethylene Oxide)
[A colorless, highly flammable, liquid cyclic ether. Diepoxybutane is primarily used for research purposes, but is also used as a curing agent for polymer resins and as a cross-linking agent for making synthetic textile fibers. Exposure to this substance can severely irritate and burn the eyes and skin and can cause liver damage. Diepoxybutane is reasonably anticipated to be a human carcinogen based on evidence of carcinogenicity in experimental animals. (NCI05) ( NCI )] (UMLS (NCI) C0059541) =Organic Chemical; Hazardous or Poisonous Substance ;
347. *Volume
[The amount of three dimensional space occupied by an object or the capacity of a space or container. ( NCI )] (UMLS (HL7) C0449468) =Quantitative Concept =Kind of quantity;
397. 1,1'-Biphenyl-4-amine
[A colorless, crystalline, solid aromatic amine that turns purple when exposed to air and emits toxic fumes when heated. p-Biphenylamine is used only in laboratory research to induce tumorigenesis. Exposure to p-biphenylamine causes headaches, lethargy, cyanosis, urinary burning and hematuria. p-Biphenylamine is a mutagen and carcinogen in humans and is associated with an increased risk of developing bladder cancer. (NCI05) ( NCI )] (UMLS (NCI) C0048112) =Organic Chemical; Hazardous or Poisonous Substance ;
348. *Volume Content
(UMLS (HL7) C1264660) =Quantitative Concept =Kind of quantity;
398. 1,1'-Dichlorodimethyl Ether
[A colorless, flammable, carcinogenic liquid with an extremely suffocating odor. Bis(Chloromethyl) Ether is used in industry as an alkylating agent, a chemical intermediate, a monitoring indicator for the presence of chloromethyl ether, and as a laboratory reagent. This substance is irritating to eyes and mucous membranes and emits toxic vapors of hydrochloric acid and other chlorinated compounds when heated to decomposition. Exposure to Bis(Chloromethyl) ether is associated with higher risk of developing lung cancer, mainly small-cell type, and the risk increases with increasing duration and cumulative exposure. (NCI05) ( NCI )] (UMLS (NCI) C0005627) =Organic Chemical; Hazardous or Poisonous Substance ;
349. *Volume Fraction
[Quotient of the volume of a component and the total volume of the system containing the component. For clinical chemistry the term component is recommended, IS0 uses substance. For clinical chemistry the term system is recommended, IS0 uses mixture. ( NCI )] (UMLS (HL7) C1264666) ;
Volume Fraction =Quantitative Concept =Kind of quantity;
399. 1,1'-Oxybisethane
[An organic compound in which two carbon atoms are linked through an oxygen atom (C-O-C). An ether may be a product of the condensation of alcohols. Ether also refers loosely to diethyl-ether, a colorless, volatile, highly inflammable liquid used in industry and biomedical research, and historically important as an anesthetic agent. In vivo, ether acts similarly to alcohol and chloroform, but its stimulant action on the heart is much more marked. Ether is a rapidly diffusible stimulant. (NCI04) ( NCI )] (UMLS (NCI) C0014994) =Organic Chemical; Pharmacologic Substance ;
=1,1'-Oxybisethane;
Ethyl Ethers;
Organic Chemical;
[CN201] ANESTHETICS INHALATION =Ethers, Cyclic;
Ethyl Ethers;
Methyl Ethers;
Phenyl Ethers;
1,1'-Oxybisethane;
ETHER 57 %;
ETHER 65 %;
ETHER 69 %
350. *Volume Rate
(UMLS (HL7) C1264672) =Quantitative Concept =Kind of quantity;
400. 1,1'-Thiobis(2-chloroethane)
[A pale yellow, oily, highly toxic, volatile, liquid alkylating compound with a sweet to garlic-like odor that evaporates to a poisonous gas. Mustard gas is a vesicant that was first used in chemical warfare in World War I, but is now only used in small amounts in research studies involving alkylating agents. Exposure to this substance is corrosive to the eyes, skin and lungs and leads to blindness and blistering of the skin and can cause severe and sometimes fatal respiratory damage. Mustard gas is a mutagen and is a known carcinogen that is associated with an increased risk of developing lung and other respiratory tract cancers. (NCI05) ( NCI )] (UMLS (NCI) C0026874) =Organic Chemical; Hazardous or Poisonous Substance ;

Buy website

Medical Clinic. Optician. Pharmacy. Physician. Travel Agency. Hotel reservation. Child Care. Education. Teachers. Lessons. Tests and Exams. Certification. Shopping Center. Store. Real Estate.
Affordable prices from $100.


 home Dictionaries Armenian-English English-Armenian MeSH Feedback  top
© 2008 -2011 Administrator MEDINDEX.AM